Thursday, January 07, 2010
JCO Editorial: Generalizing the Results of Cancer Clinical Trials
See also Table 1:Occult Influences of the Clinical Trial Setting on the Generalizability of Results - Differences in the Patient Population
"As clinical trials increasingly become a global enterprise, issues of generalizability will increase in importance. It will be essential to ensure that the conduct of a trial and its subsequent reporting include attention to aspects that influence generalizability, so that determinations of whether observations and conclusions reached in one geographic setting, or within one type of health care system, are applicable to the policy makers and practitioners from other settings."
JCO Editorial: Biomarkers of Antiangiogenic Therapy: How Do We Move From Candidate Biomarkers to Valid Biomarkers?
"Thus, these candidate biomarkers should continue to be actively explored in trials of antiangiogenic agents in patients, to get closer to the goal of improving and individualizing cancer therapy."
Journal of Oncology — An Open Access Journal Role of lymphadenectomy in early and advanced ovarian cancer
click on 'pdf' top right hand corner
full free access: Journal of Oncology —Role of lymphadenectomy in early and advanced ovarian cancer
full free access - click on the 'pdf' box - top right corner
There Is a New Pre-Symptomatic Screening Test for Ovarian Cancer Coming From Arrayit Corporation, and It Will Be Available Soon - OvaDx(TM)
Note: The test will soon be submitted to the FDA for approval
BJC - Abstract: Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity
Note: ovarian cancer patients were included in this phase 1 study but abstract gives limited information
DNAPrint Genomics - Ovanome
Note: As far as I can tell this test still needs approvals
OVANOME:
Ovanome is a genetic test for predicting an ovarian cancer patient’s response to first-regimen Taxol¹ and carboplatin (TC) chemotherapy. 30% of chemo-naive women do not respond to TC treatment and DNAPrint™ research shows that this problem is largely a function of genetic polymorphism.
Biotech News & Online Store - Belinostat phase II trial initiated in platinum-resistant ovarian cancer by the Gynecologic Oncology Group (GOG) supported by
The study:
A Phase II evaluation of Belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.
UK: i LEARN u LEARN events
Our ‘i LEARN – u LEARN’ events are taking place in March 2010.
These are six interactive meetings that will be held in
* London (1 & 17 March 2010)
* Belfast (4 March 2010)
* Cardiff (9 March 2010)
* Liverpool (12 March 2010)
* Edinburgh (15 March 2010)
At these meetings, you can find out more about regulation in the health sector and take part in various activities where you can lend your voice to some ongoing debates. We will be supported at all meetings by representatives from the health professional regulatory bodies. Places at these meetings are limited, so we encourage you to register early to attend these events. You can register by emailing us at reception@chre.org.uk or by calling us on 020 7389 8030.
Pallimed: A Hospice & Palliative Medicine Blog
This most recent update has some good information and includes some Twitter comments regarding Palliative/Hospice care comments.
Wednesday, January 06, 2010
Subscribe to:
Posts
(
Atom
)
